Expert Interview
Discussing new data on AstraZeneca’s Imfinzi (durvalumab) in NMIBC and Roche’s Tecentriq (atezolizumab) in MIBC Presented at ESMO 2025
Ticker(s): AZN, RHHBY, NTRA, PFE, IBRX, CGON, MRK, JNJ, URGN, AURA, TARA, BMYInstitution: UT Southwestern Medical Center at Dallas
- Professor, Vice Chair of Clinical Affairs, Chief of Urologic Oncology at UT Southwestern Medical Center at Dallas.
- Currently manages 200+ patients with Non-Muscle Invasive Bladder Cancer.
- Published hundreds of research articles and several book chapters on urologic care and procedures, and serves as editorial reviewer for medical periodicals such as the Journal of Urology, European Urology, Cancer, Urologic Oncology, and the British Journal of Urology International.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
